骨质疏松序贯治疗:下一步用哪种药?
本文讨论骨质疏松症序贯治疗策略。长期双膦酸盐(BPs)虽罕见但存在并发症风险,且药物在骨内储存数年;而不储存于骨的药物如阿巴洛肽、特立帕肽、地舒单抗和罗莫索单抗停药后骨吸收反弹致骨量快速丢失,故须后续使用抗骨吸收药物。Kendler等在JCEM报道阿仑膦酸钠可保留地舒单抗治疗期间获得的骨量。
要点
- 双膦酸盐长期治疗虽罕见并发症但改变处方模式,且药物在骨内储存数年。
- 阿巴洛肽、特立帕肽、地舒单抗和罗莫索单抗不储存于骨,停药后骨吸收反弹致骨量快速丢失。
- 使用上述药物后必须序贯抗骨吸收药物;Kendler等报道阿仑膦酸钠可保留地舒单抗获得的骨量。
核心结论
- 使用不储存于骨的骨质疏松药物(如阿巴洛肽、特立帕肽、地舒单抗和罗莫索单抗)后,必须序贯使用抗骨吸收药物以防止骨量快速丢失。
- Kendler等在JCEM报道阿仑膦酸钠可保留地舒单抗治疗期间获得的骨量。
研究设计与样本
- 原文为针对骨质疏松序贯治疗的评论文章,引用Kendler等发表于JCEM的研究。
主要发现
- 双膦酸盐长期治疗虽罕见但存在并发症风险,且药物在骨内储存数年。
- 阿巴洛肽、特立帕肽、地舒单抗和罗莫索单抗不储存于骨,停药后骨吸收反弹致骨量快速丢失。
- Kendler等报道阿仑膦酸钠可保留地舒单抗治疗期间获得的骨量。
临床怎么用
- 使用不储存于骨的骨质疏松药物(如阿巴洛肽、特立帕肽、地舒单抗和罗莫索单抗)后,必须序贯使用抗骨吸收药物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The proliferation of drugs with unique modes of action for treating osteoporosis has been most welcome. Fear of complications, even though rare, associated with long-term bisphosphonates (BPs) changed prescribing patterns. The BPs are stored in bone for years. Drugs not stored in bone; for example, abaloparatide, teriparatide, denosumab, and romosozumab have expanded our armamentarium for treating osteoporosis but have brought new challenges. Bone accrued during treatment with the last 3 drugs, and perhaps abaloparatide, is lost rapidly after their withdrawal due to rebound increase in bone resorption. Treatment with these drugs must be followed by administration of an antiresorptive agent. The article by Kendler et al. (1) in this issue of JCEM reports alendronate preserves bone accrued during administration of denosumab.
引用
- Lukert BP. Which Drug Next? Sequential Therapy for Osteoporosis. J Clin Endocrinol Metab. 2020. PMID: 31922566. doi:10.1210/clinem/dgaa007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。